EXOC3-AS1: A Protein Target for Cancer and Other Diseases (G116349)

Target Name: EXOC3-AS1

NCBI ID: G116349

EXOC3-AS1

EXOC3-AS1: A Protein Target for Cancer and Other Diseases

EXOC3-AS1 (EXAS1_HUMAN), also known as human EXOC3-AS1, is a protein that is expressed in various tissues of the human body. It is a key regulator of the cell cycle, and its dysfunction has been implicated in a number of diseases , including cancer. As a drug target or biomarker, EXOC3-AS1 is of great interest to researchers because it can be targeted with small molecules, making it an attractive target for drug development.

EXOC3-AS1 functions as a negative regulator of the G1/S transition, which is the critical step in the cell cycle where the cell prepares for cell division. During the G1 phase, the cell grows, replicates its DNA, and prepares for the S phase, where the cell divides. The G1/S transition is critical for the cell to ensure that it has enough resources for cell division, and EXOC3-AS1 plays a crucial role in this process.

EXOC3-AS1 is composed of a N-terminal transmembrane domain, a coiled-coil region, and a C-terminal protein domain. The transmembrane domain is responsible for the protein's ability to interact with the cell membrane, while the coiled-coil region is responsible for the protein's stability and stability. The C-terminal protein domain is responsible for the protein's unique structure and function, as it contains the regions that interact with other proteins and factors to regulate the G1/S transition.

EXOC3-AS1 has been shown to play a critical role in a variety of diseases, including cancer. For example, EXOC3-AS1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This downregulation has has been attributed to various mechanisms, including increased levels of stress, decreased levels of nutrients, and disruptions in the cell cycle.

In addition to its role in cancer, EXOC3-AS1 has also been shown to be involved in a number of other cellular processes. For example, EXOC3-AS1 has been shown to play a critical role in the regulation of cell adhesion, as well as the development and maintenance of the nervous system. It has also been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway.

Due to its involvement in a number of cellular processes, EXOC3-AS1 has naturally become a target for drug development. Small molecules have been shown to be effective in inhibiting EXOC3-AS1 function, and a number of compounds have been shown to be promising candidates for further development as potential drugs.

One of the advantages of targeting EXOC3-AS1 is that it is a relatively small protein, which makes it easier to design and develop small molecules. Additionally, because EXOC3-AS1 is involved in a number of cellular processes, targeting it with small molecules may not have unintended consequences on other cellular processes.

Another advantage of targeting EXOC3-AS1 is that it has been shown to be a good biomarker for a variety of diseases, including cancer. This means that researchers can use EXOC3-AS1 as a diagnostic tool to test for the presence of disease, as well as as a target for drug development.

In conclusion, EXOC3-AS1 is a protein that is expressed in various tissues of the human body and plays a crucial role in the cell cycle. Its dysfunction has been implicated in a number of diseases, including cancer. As a drug target or biomarker, EXOC3-AS1 is of great interest to researchers because it can be targeted with small molecules, making it an attractive target for drug development. Additionally, its involvement in a number of cellular processes makes it a promising target for the development of new therapies for a variety of diseases.

Protein Name: EXOC3 Antisense RNA 1

The "EXOC3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EXOC3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets